Compare BZH & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZH | AUPH |
|---|---|---|
| Founded | 1985 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 672.0M | 1.6B |
| IPO Year | 1994 | 1999 |
| Metric | BZH | AUPH |
|---|---|---|
| Price | $20.22 | $15.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $32.00 | $17.25 |
| AVG Volume (30 Days) | 410.9K | ★ 1.1M |
| Earning Date | 01-29-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.52 | 0.55 |
| Revenue | ★ $2,371,555,000.00 | $265,808,000.00 |
| Revenue This Year | $7.40 | $21.76 |
| Revenue Next Year | $12.09 | $16.45 |
| P/E Ratio | ★ $13.34 | $28.99 |
| Revenue Growth | 1.77 | ★ 20.62 |
| 52 Week Low | $17.37 | $6.55 |
| 52 Week High | $29.30 | $16.54 |
| Indicator | BZH | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 36.50 | 55.71 |
| Support Level | $19.91 | $15.64 |
| Resistance Level | $22.04 | $16.54 |
| Average True Range (ATR) | 0.50 | 0.38 |
| MACD | -0.16 | -0.08 |
| Stochastic Oscillator | 10.91 | 57.55 |
Beazer Homes USA Inc is an construction company that focuses on residential construction. The company specializes in single-family housing and multi-unit building construction in states and metro markets. Beazer Homes builds homes and communities that target first-time, move-up, and luxury homebuyers with an average selling price of roughly $300,000. From a geographic perspective, home sales in the western and eastern United States have been the sources of revenue for the company. Its segments involve: West segment that includes Arizona, California, Nevada, and Texas; East segment that includes Delaware, Indiana, Maryland, Tennessee, and Virginia; and Southeast segment which includes Florida, Georgia, North Carolina, and South Carolina.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.